Asia-Pacific Journal of Oncology, Год журнала: 2024, Номер unknown
Опубликована: Дек. 27, 2024
The spread of cancer and huge number related deaths has made it imperative for scientist to search new diagnostic, prognostic treatment tools its effective management. Chimeric Antigen Receptor (CAR) T-cell (CAR-T) therapy been brought into limelight as novel strategy cancer. In this review we briefly introduced the CAR-T highlighting successful application various cancers along with possibility integrating induced pluripotent stem cell (iPSC) technology overcome intrinsic limitation. mechanism is based on isolation white blood cells through leukapheresis from patients’ or healthy donors followed by T-cells (a type immune cells). isolated are engineered using a viral vector other methods incorporate CAR gene expanded in lab. This modification enables T distinguish attack antigens surfaces cells. However, approach not without inherent limitations. notable limitation exhaustible availability within donor patient system, which can restrict feasibility effectiveness therapeutic intervention. A potential solution may lie synergizing technology. iPSC lies ability provide an endless supply resources. substantial amount research revealed production human Therefore, such combinatorial utilizing mounting immunological against continues iPSCs prove revolutionary designing pragmatic treatment.
Язык: Английский
